FOURTH QUARTER IN BRIEF
- Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis (December 1)
- Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod (December 5)
- Active Biotech announces outcome of the Company's rights issue (December 6)
- Preclinical data of tasquinimod presented at ASH (December 14)
- Active Biotech provides update on the scheduled clinical program for 2024 (December 22)
OTHER SIGNIFICANT EVENTS JAN - DEC 2023
- Active Biotech confirmed positive clinical safety profile of laquinimod eye drops (January 30)
- Safety and preliminary efficacy of naptumomab in combination with durvalumab presented at AACR 2023 (April 19)
- Positive interim data from the ongoing study of tasquinimod in heavily pre-treated patients with relapsed and refractory multiple myeloma presented at ASCO 2023 (May 26)
- Positive safety and tolerability in clinical phase I study and preclinical ocular biodistribution data supporting the further development of laquinimod eye drops for inflammatory eye diseases were established (May 30)
- New preclinical data regarding tasquinimod's anti-fibrotic effects in myelofibrosis were presented at EHA 2023 (June 10)
- Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31)
- Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (September 11)
- Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting is made available on Active Biotech's website (September 13)
FINANCIAL SUMMARY
| SEK M | Oct-Dec | Jan-Dec | ||
| 2023 2022 | 2023 2022 | |||
| Net sales | - | - | - | - |
| Operating profit/loss | -12.8 | -15.2 | -46.5 | -57.9 |
| Profit/loss after tax | -12.5 | -15.0 | -45.8 | -58.4 |
| Earnings per share (SEK) | -0.04 | -0.06 | -0.17 | -0.25 |
| Cash and cash equivalents (at close of period) | 36.2 | 41.8 | ||
The report is also available at www.activebiotech.com.
This information was provided to the media, through the agency of the contact persons set out below, for publication on February 8, 2024 at 08.30 CET.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in clinical development for treatment of non-infectious uveitis and a clinical phase I study with a topical ophthalmic formulation has been concluded. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.
